Source: Annual Congress 2002 - The role of inflammatory markers in children with asthma
Disease area: Airway diseases, Paediatric lung diseases

Abstract

ECP (eosinophil cationic protein) may be assayed in most biological fluids as a marker of eosinophil activity and turnover. In asthma, ECP has been related to the inflammatory activity. However, the majority of reports have focused on the evaluation of the protein in serum and sputum. This study sought to assess the possible clinical significance of determining ECP levels in saliva of asthmatic children. ECP was quantified in saliva obtained from 22 patients, aged 6-12 years, with mild to moderate asthma, before and after 8 weeks treatment with fluticasone propionate. The efficacy of the treatment was assessed by the significant increase of FEV1 (p=0.014, paired t-test; Spearmans r=0.706, p<0.000). A significant correlation was obtained between the levels of ECP in saliva before and after treatment (Spearmans r=0.466, p=0.029) and the levels of ECP were significantly reduced (p=0.032, paired t-test of the log-transformed data). These data suggest that, especially in the pediatric mild to moderate asthmatic patient, determination of ECP in saliva may serve as a convenient, less invasive and reliable indicator for clinical activity monitoring.

Rating:

Share or cite this content

Citations should be made in the following way:
P. Panaghiotopoulou-Gartagani, V. Miligkos, C. Agrafioti, K. Spanou, M. Kanariou, O. Martinopoulou, A. Xipolita-Zachariadi (Athens, Greece). ECP in saliva: marker of disease activity in mild to moderate pediatric asthma. Eur Respir J 2002; 20: Suppl. 38, 928

Member's Comments

No comment yet.

Related content which might interest you: Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity Source: ERJ Open Res, 7 (3) 00984-2020; 10.1183/23120541.00984-2020 Year: 2021 Serum eosinophil cationic protein as a marker of disease severity in patients with bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 51s Year: 2001 Additional value of spirometry in risk assessment of acute respiratory disease in winter among patients with mild to moderate asthma or COPD Source: Eur Respir J 2002; 20: Suppl. 38, 473s Year: 2002 EBC periostin concentration in children with mild-to moderate asthma Source: International Congress 2019 – Asthma biomarkers, diagnostics and risk factors Year: 2019 Study on levels of high sensitivity C reactive protein in asthmatic patients during exacerbation and remission and its correlation with pulmonary function Source: Annual Congress 2007 - Mechanisms of airway inflammation Year: 2007 Effect of one moderate or mild exacerbation on lung function and serum inflammatory markers in ex smokers patients with COPD Source: Annual Congress 2009 - Cellular-tissue modifications and functional evaluation in COPD patients Year: 2009 Serum ECP levels do not correlate with degree of bronchial hyperresponsiveness in patients with cough variant asthma Source: Eur Respir J 2005; 26: Suppl. 49, 584s Year: 2005 Serum levels of IL-6 in adult patients with moderate to severe asthma. Source: International Congress 2017 – Novel mechanisms in asthma Year: 2017 Bronchial inflammation without asthma symptoms, relation to low neutrophil activity in serum Source: Eur Respir J 2002; 20: Suppl. 38, 143s Year: 2002 Cellular inflammatory pattern in induced sputum among patients with stable moderate or severe asthma Source: Annual Congress 2010 - Biomarkers and Diagnosis of asthma and allergic respiratory diseases Year: 2010 Baseline data and responses to oral steroid intervention in asthma and COPD: interim report from the BIOAIR EU study Source: Annual Congress 2007 - Asthma subphenotypes Year: 2007 Measuring inflammation inpaediatric severe asthma: biomarkers in clinical practice Source: Breathe, 16 (1) 190301; 10.1183/20734735.0301-2019 Year: 2020 Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021 Does eosinophil cationic protein (ECP) predict asthma outcome and response to treatment in asthmatic patients? Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Sputum eosinophilia in the diagnosis and management of asthma of moderate severity in adults Source: Eur Respir J 2007; 30: Suppl. 51, 587s Year: 2007 Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017 Year: 2018 Both moderate and severe exacerbations accelerate physical activity decline in COPD patients Source: Eur Respir J, 51 (1) 1702110; 10.1183/13993003.02110-2017 Year: 2018 Sputum eosinophil percentages during a moderate exacerbation of asthma and during a natural cold Source: Eur Respir J 2002; 20: Suppl. 38, 508s Year: 2002 Blood eosinophil in smokers and mild and moderate COPD patients Source: International Congress 2017 – Latest insights into the management of chronic lung diseases Year: 2017